Two approaches to drug discovery in SOD1-mediated ALS. - Wikidata - awgldk - TriplyDB

Two approaches to drug discovery in SOD1-mediated ALS.

Two approaches to drug discovery in SOD1-mediated ALS.

http://www.wikidata.org/entity/Q33255028

about

TDP-43 identified from a genome wide RNAi screen for SOD1 regulators Human embryonic stem cell-derived motor neurons expressing SOD1 mutants exhibit typical signs of motor neuron degeneration linked to ALS.Chemical library screening identifies a small molecule that downregulates SOD1 transcription for drugs to treat amyotrophic lateral sclerosis.A high-throughput screen to identify inhibitors of SOD1 transcription.A screen to identify cellular modulators of soluble levels of an amyotrophic lateral sclerosis (ALS)-causing mutant SOD1.Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models High content analysis in amyotrophic lateral sclerosis.Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response.50bp deletion in the promoter for superoxide dismutase 1 (SOD1) reduces SOD1 expression in vitro and may correlate with increased age of onset of sporadic amyotrophic lateral sclerosis

P2860

Q28482611-DBC0ECF0-B765-4793-A992-FB79C94D0A93 Q30486275-E732947C-7407-41E6-8882-1A6E3A147F8F Q33833426-1F35AB9B-E1EB-4E35-8543-DE80DEB38ECC Q33850895-2006868A-4E79-4B20-B13A-0A4147EDDB52 Q34005076-75F82282-DEE8-46A0-8FCC-460079D2E773 Q34234969-3DC3A1A5-364A-4F6E-8322-8B15CD570EC4 Q39037865-B13793F8-E68E-4DEA-9BF0-A9D0F3ADD4BB Q39113607-866D603B-3186-43CD-A230-DAAA3E2BFF3A Q57273767-44EDCFCF-36B3-4490-BB5B-FC955FDCB279

P2860

Two approaches to drug discovery in SOD1-mediated ALS.

http://www.wikidata.org/entity/Q33255028

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Two approaches to drug discovery in SOD1-mediated ALS.

@ast

Two approaches to drug discovery in SOD1-mediated ALS.

@en

type

label

Two approaches to drug discovery in SOD1-mediated ALS.

@ast

Two approaches to drug discovery in SOD1-mediated ALS.

@en

prefLabel

Two approaches to drug discovery in SOD1-mediated ALS.

@ast

Two approaches to drug discovery in SOD1-mediated ALS.

@en

P1433

Q33255028-68E929A8-9510-4C26-8189-DACECA7B56A0

P1476

Q33255028-7F83BD4E-B3D0-4FAC-AD4A-15130F844AAD

P2093

Q33255028-275261BA-A214-4FC2-9E9F-C378A0FC0EFD

Q33255028-34CC6829-F749-4C48-8295-D0E6745039FE

Q33255028-705F06B5-4EAD-460D-97CD-25B002E796CB

Q33255028-8832F756-99DB-4725-950C-0A8E8EEA0308

Q33255028-8B6D4F9B-0F33-4F82-A9A2-98B50649DDE0

Q33255028-91FD8830-E1D5-42AE-8BC1-F1F969AAAAFD

Q33255028-92979A2E-4FE0-4A89-AE75-6448786E9B84

Q33255028-C173D83E-A33B-45BE-A8E4-A620DBDC30C9

P2860

Q33255028-2114F018-4D79-4B81-81CF-BC10DF8DBCF9

Q33255028-2803E956-AF9F-451E-BFA7-B78E3CCA12B0

Q33255028-4436D0FC-3EBA-41AF-8B92-93B0AB4A9C51

Q33255028-48582EDF-AAE0-46CC-BBC8-025FC66C8C3D

Q33255028-562DF083-FD68-49D3-89B3-696B6AE0FA85

Q33255028-59D3325D-B3F3-41F5-A8A4-F2C33C625FD4

Q33255028-6ADE9E9E-2061-4937-AE3F-1C45EB8640D1

Q33255028-96F998FE-B827-4DFC-9A63-FF59D47494B7

Q33255028-C757A78D-7555-47FA-9185-F8F15BF181F8

Q33255028-D24A2297-C1F6-4927-954D-78AFFA9798F7

P304

Q33255028-629A1DFE-FEFF-4A9B-A8C4-301C3E1F3B0F

P31

Q33255028-251BA3AB-9248-4461-BA60-232E32F42B1B

P356

Q33255028-70D0B6FF-C429-4DD5-AFD6-FF813B8F63FD

P433

Q33255028-3E1DBE16-D94F-4324-B8AC-73BA3E7DBED4

P478

Q33255028-891F30CA-4FBA-4E5C-8940-A90046E8F753

P50

Q33255028-7476B433-2629-4C74-8FBE-80862A83D588

P577

Q33255028-DFAC619D-796E-4FDA-94FF-D4C4592EFA3A

P5875

Q33255028-CA141BD9-58E6-4CEF-A6DA-BC1D1D86B9EF

P698

Q33255028-9D899CF1-6859-4DCC-9864-4171C69BF4AD

P921

Q33255028-AE2C777C-F40D-4C49-B6E3-46F1E132AC25

P356

1087057106290937

P1433

Journal of Biomolecular Screening

P1476

Two approaches to drug discovery in SOD1-mediated ALS.

@en

P2093

Aleksey G Kazantsev

http://www.w3.org/2001/XMLSchema#string

Deborah E Russel

http://www.w3.org/2001/XMLSchema#string

Jake Ni

http://www.w3.org/2001/XMLSchema#string

Kristen E Auwarter

http://www.w3.org/2001/XMLSchema#string

Li-An Yeh

http://www.w3.org/2001/XMLSchema#string

Marcie Glicksman

http://www.w3.org/2001/XMLSchema#string

Michele M Maxwell

http://www.w3.org/2001/XMLSchema#string

Wendy J Broom

http://www.w3.org/2001/XMLSchema#string

P2860

A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2

A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis.

DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4)

Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis

CuZn superoxide dismutase (SOD-1):tetanus toxin fragment C hybrid protein for targeted delivery of SOD-1 to neuronal cells.

Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.

P304

729-735

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1087057106290937

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6859297

http://www.w3.org/2001/XMLSchema#string

P698

16928982

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis